Deeper Knowledge, Faster

  • Identify first generic entrants
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Fuji
Cantor Fitzgerald
Express Scripts
Chinese Patent Office
Mallinckrodt
Covington
Citi
US Department of Justice
AstraZeneca
Daiichi Sankyo

Generated: January 21, 2018

DrugPatentWatch Database Preview

Details for Patent: 7,320,802

« Back to Dashboard

Summary for Patent: 7,320,802
Title:Methods of treatment using nanoparticulate fenofibrate compositions
Abstract:The present invention is directed to fibrate compositions having improved pharmacokinetic profiles and reduced fed/fasted variability. The fibrate particles of the composition have an effective average particle size of less than about 2000 nm.
Inventor(s): Ryde; Tuula (Malvern, PA), Gustow; Evan E. (Villanova, PA), Ruddy; Stephen B. (Schwenksville, PA), Jain; Rajeev (Collegeville, PA), Patel; Rakesh (Bensalem, PA), Wilkins; Michael John (Midleton, IE)
Assignee: Elan Pharma International, Ltd. (Athlone, County Westmath, IL) Fournier Laboratories Ireland Ltd. (Cork, IL)
Application Number:10/692,855
Patent Claim Types:
see list of patent claims
Use; Composition; Dosage form; Formulation;

Drugs Protected by US Patent 7,320,802

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Abbvie TRICOR fenofibrate TABLET;ORAL 021656-001 Nov 5, 2004 AB RX Yes No ➤ Subscribe ➤ Subscribe ADJUNCTIVE THERAPY TO DIET IN ADULTS TO REDUCE LDL-C, TRIGLYCERIDES AND APO B, AND INCREASE HDL-C IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA OR MIXED DYSLIPIDEMIA (TYPES IIA, IIB) AND TO TREAT HYPERTRIGLYCERIDEMIA (TYPES IV, V) ➤ Subscribe
Abbvie TRICOR fenofibrate TABLET;ORAL 021656-002 Nov 5, 2004 AB RX Yes Yes ➤ Subscribe ➤ Subscribe ADJUNCTIVE THERAPY TO DIET IN ADULTS TO REDUCE LDL-C, TRIGLYCERIDES AND APO B, AND INCREASE HDL-C IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA OR MIXED DYSLIPIDEMIA (TYPES IIA, IIB) AND TO TREAT HYPERTRIGLYCERIDEMIA (TYPES IV, V) ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 7,320,802

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,811,767 Liquid droplet aerosols of nanoparticulate drugs ➤ Subscribe
7,459,283 Nanoparticulate compositions having lysozyme as a surface stabilizer ➤ Subscribe
8,236,352 Glipizide compositions ➤ Subscribe
6,316,029 Rapidly disintegrating solid oral dosage form ➤ Subscribe
8,323,641 Nanoparticulate compositions having lysozyme as a surface stabilizer ➤ Subscribe
8,293,277 Controlled-release nanoparticulate compositions ➤ Subscribe
7,244,451 Methods of making nanoparticulate drug compositions comprising copolymers of vinyl pyrrolidone and vinyl acetate as surface stabilizers ➤ Subscribe
7,927,627 Nanoparticulate fibrate formulations ➤ Subscribe
7,850,995 Bioadhesive nanoparticulate compositions having cationic surface stabilizers ➤ Subscribe
7,521,068 Dry powder aerosols of nanoparticulate drugs ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 7,320,802

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 040110 ➤ Subscribe
Argentina 072134 ➤ Subscribe
Argentina 072135 ➤ Subscribe
Austria 293959 ➤ Subscribe
Austria 333265 ➤ Subscribe
Austria 343376 ➤ Subscribe
Austria 381317 ➤ Subscribe
Austria 385777 ➤ Subscribe
Austria 419834 ➤ Subscribe
Austria 464880 ➤ Subscribe
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

QuintilesIMS
Express Scripts
US Department of Justice
Citi
Colorcon
Cerilliant
Merck
UBS
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot